Methylation study of a population environmentally exposed to arsenic in drinking water.

Methylation is considered the detoxification pathway for inorganic arsenic (InAs), an established human carcinogen. Urinary speciation analysis is used to assess the distribution of metabolites [monomethylarsonate (MMA), dimethylarsinate (DMA), and unmethylated arsenic (InAs)], as indicators of methylation capacity. We conducted a large biomarker study in northern Chile of a population chronically exposed to high levels of arsenic in drinking water. We report the results of the methylation study, which focused on the effects of exposure and other variables on the percent InAs, MMA, DMA, and the ratio of MMA to DMA in urine. The study consisted of 122 people in a town with arsenic water levels around 600 micrograms/l and 98 participants in a neighboring town with arsenic levels in water of about 15 micrograms/l. The corresponding mean urinary arsenic levels were 580 micrograms/l and 60 micrograms/l, of which 18.4% and 14.9% were InAs, respectively. The main differences were found for MMA:DMA; exposure, smoking, and being male were associated with higher MMA:DMA, while longer residence, Atacameño ethnicity, and being female were associated with lower MMA:DMA. Together, these variables explained about 30% of the variability in MMA:DMA. Overall, there was no evidence of a threshold for methylation capacity, even at very high exposures, and the interindividual differences were within a much wider range than those attributed to the variables investigated. The differences in percent InAs were small and within the ranges of other studies of background exposure levels. The biological significance of MMA:DMA, which was more than 1.5 times greater in the exposed group, and its relationship to sex, length of exposure, and ethnicity need further investigation because its relevance to health risk is not clear. Imagesp620-aFigure 1.Figure 2.Figure 2.Figure 2.Figure 2.

[1]  P. Mushak,et al.  Risk and revisionism in arsenic cancer risk assessment. , 1995, Environmental health perspectives.

[2]  E. I. Hamilton,et al.  Arsenic in the environment part II: Human health and ecosystem effects , 1995 .

[3]  Alan C. Nye,et al.  Investigation of arsenic exposure from soil at a superfund site. , 1995, Environmental research.

[4]  B. D. Beck,et al.  Response to Smith et al , 1995, Environmental Health Perspectives.

[5]  H. Aposhian,et al.  Arsenic binding proteins of mammalian systems: I. Isolation of three arsenite-binding proteins of rabbit liver. , 1994, Toxicology.

[6]  M. Gonsebatt,et al.  Lymphocyte replicating ability in individuals exposed to arsenic via drinking water. , 1994, Mutation research.

[7]  A. Smith,et al.  Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  M. Vahter Species differences in the metabolism of arsenic compounds , 1994 .

[9]  B. D. Beck,et al.  Arsenic risk assessment. , 1994, Environmental health perspectives.

[10]  L K Lowry,et al.  Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. , 1993, American Industrial Hygiene Association journal.

[11]  N K Spurr,et al.  Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. , 1993, Carcinogenesis.

[12]  D. Thompson,et al.  A chemical hypothesis for arsenic methylation in mammals. , 1993, Chemico-biological interactions.

[13]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[14]  A. Lafuente,et al.  Enhanced glutathione S-transferase activity and glutathione content in human bladder cancer. Followup study: influence of smoking. , 1993, The Journal of urology.

[15]  A. Smith,et al.  Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. , 1993, Environmental research.

[16]  T. Kuo,et al.  Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. , 1992, British Journal of Cancer.

[17]  A. Smith,et al.  Cancer risks from arsenic in drinking water. , 1992, Environmental health perspectives.

[18]  M. Mass Human carcinogenesis by arsenic , 1992, Environmental geochemistry and health.

[19]  A. Smith,et al.  Arsenic ingestion and internal cancers: a review. , 1992, American journal of epidemiology.

[20]  P. Vineis,et al.  Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. , 1991, Pharmacogenetics.

[21]  D. Kalman,et al.  On-line photo-oxidation for the determination of organoarsenic compounds by atomic-absorption spectrometry with continuous arsine generation. , 1991, Talanta.

[22]  A. Tanaka,et al.  Effects of glutathione depletion on the acute nephrotoxic potential of arsenite and on arsenic metabolism in hamsters. , 1990, Toxicology and applied pharmacology.

[23]  J. Buchet,et al.  Inorganic arsenic methylation by rat tissue slices. , 1990, Toxicology.

[24]  H. Aposhian,et al.  Newer Developments in Arsenic Toxicity , 1989 .

[25]  C. Chen,et al.  Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. , 1989, American journal of epidemiology.

[26]  S. Okada,et al.  Mutagenicity of dimethylated metabolites of inorganic arsenics. , 1989, Chemical & pharmaceutical bulletin.

[27]  J. Buchet,et al.  Role of thiols in the in-vitro methylation of inorganic arsenic by rat liver cytosol. , 1988, Biochemical pharmacology.

[28]  R. Weinshilboum Pharmacogenetics of methylation: relationship to drug metabolism. , 1988, Clinical biochemistry.

[29]  J. Buchet,et al.  Study of factors influencing the in vivo methylation of inorganic arsenic in rats. , 1987, Toxicology and applied pharmacology.

[30]  S. Charbonneau,et al.  Metabolism of inorganic arsenic (74As) in humans following oral ingestion. , 1979, Toxicology and applied pharmacology.

[31]  E. Crecelius Modification of the arsenic speciation technique using hydride generation , 1978 .

[32]  J. Borgoño,et al.  Arsenic in the drinking water of the city of Antofagasta: epidemiological and clinical study before and after the installation of a treatment plant. , 1977, Environmental health perspectives.

[33]  D. Chakraborti,et al.  Arsenic in ground water in six districts of West Bengal, India: the biggest arsenic calamity in the world. Part I. Arsenic species in drinking water and urine of the affected people , 1995 .

[34]  S. Horiguchi,et al.  Dimethylarsenic acid induces tetraploids in Chinese hamster cells , 1992, Bulletin of environmental contamination and toxicology.

[35]  D. Shirachi,et al.  Cytotoxicity of inorganic and organic arsenics in cell culture. , 1992, Proceedings of the Western Pharmacology Society.

[36]  T. Sh,et al.  Cytotoxicity of inorganic and organic arsenics in cell culture. , 1992 .

[37]  T. Levine Special report on ingested inorganic arsenic : skin cancer, nutritional essentiality , 1988 .

[38]  C. Richard Cothern,et al.  Risk assessment and risk management of industrial and environmental chemicals , 1988 .

[39]  M. Vahter Metabolism of arsenic , 1983 .

[40]  H. Roels,et al.  Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers , 1981, International archives of occupational and environmental health.

[41]  P. Gomez-Caminero,et al.  Arsenic and arsenic compounds. , 1980, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.

[42]  J. Harington Environmental Health Perspectives , 1976 .